Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Editas Medicine (EDIT) has reported Long-Term Investments for 5 consecutive years, with $39.2 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Long-Term Investments fell 18.5% year-over-year to $39.2 million; the TTM figure through Jun 2024 stood at $39.2 million (down 18.5% YoY), while the FY2023 annual figure was $104.0 million, up 11.74% from the prior year.
• Long-Term Investments slipped to $39.2 million in Q2 2024 per EDIT's latest filing, from $80.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $120.1 million in Q4 2021 and bottomed at $39.2 million in Q2 2024.
• Historically, Long-Term Investments has averaged $82.3 million across 5 years, with a median of $85.5 million in 2021.
• Annual changes were most pronounced in 2021 — Long-Term Investments jumped 115.65% — and 2022, when it tumbled 40.68%.
• Editas Medicine's Long-Term Investments stood at $109.7 million in 2020, then advanced by 9.49% to $120.1 million in 2021, then declined by 22.47% to $93.1 million in 2022, then gained by 11.74% to $104.0 million in 2023, then sank by 62.32% to $39.2 million in 2024.
• Business Quant data shows EDIT's Long-Term Investments at $39.2 million in Q2 2024, $80.6 million in Q1 2024, and $104.0 million in Q4 2023.